Moazzam Shahzad

1 month ago | nature.com | Aqeeb ur Rehman |Moazzam Shahzad |Faiz Anwer |Joseph McGuirk |Mohamad Mohty |Nausheen Ahmed | +1 more

AbstractMeasurable residual disease (MRD) testing is emerging as a crucial prognostic and treatment-guiding tool in multiple myeloma (MM). Despite its potential, routine clinical adoption remains inconsistent. This study aimed to explore oncologists’ perspectives on MRD testing and identify barriers and facilitators to its clinical integration. A cross-sectional, modified Delphi survey was conducted among hematologists and oncologists globally, and 115 responses were received.

Oct 13, 2023 | nature.com | Moazzam Shahzad |Andrea Nguyen |Nausheen Ahmed |Anurag Singh |Joseph McGuirk |Muhammad Kashif Amin | +1 more

This is a preview of subscription content, access via your institution Access options Subscribe to this journalReceive 12 print issues and online access$259.00 per yearonly $21.58 per issueRent or buy this articlePrices vary by article typefrom$1.95to$39.95Prices may be subject to local taxes which are calculated during checkout Data availabilityThe original contributions presented in the study are included in the article/supplementary material.